Last reviewed · How we verify
Tears Again
At a glance
| Generic name | Tears Again |
|---|---|
| Sponsor | Trima, Israel Pharmaceutical Products |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Gland Expression on the Regeneration of Meibomian Gland (NA)
- Assessment of the Safety and the Performance of the SAGITTA EVL R Stems in Hip Arthroplasties
- Pre-labor Ultrasound as a Visual Biofeedback Device for Maternal Pushing Education (NA)
- Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops (NA)
- Low Temperature Plasma Ablation Combined Lacrimal Duct Catheterization in the Treatment of Lacrimal Duct Obstructive (NA)
- Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again® (NA)
- Corneal Biomechanical Changes of Allergic Conjunctivitis
- Clinical Study to Evaluate the Efficacy of Ectoin® Containing Eye Spray for Treatment of Dry Eye Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tears Again CI brief — competitive landscape report
- Tears Again updates RSS · CI watch RSS
- Trima, Israel Pharmaceutical Products portfolio CI